Jean Jacques Bienaime
Director at BioMarin Pharmaceutical; Director at Incyte; Director at Ascendis Pharma A/S. Based in Lexington, Massachusetts.
- Rank
- 2620th of 14,644
- Companies held
- 4
- Largest holding
- BMRN, 92.1% of total
- Latest SEC filing
- Aug 17, 2026
- Listed but not counted
- $742K
What the $48.1M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical BMRN Common Stock | Directly | 473,792 | $61.42 | $29.1M | 60.5% | Form 4, May 20, 2024 |
| BioMarin Pharmaceutical BMRN Common Stock | Shares held by Jean-Jacques Bienaime Family Trust | 247,333 | $61.42 | $15.2M | 31.6% | Form 4, May 20, 2024 |
| Incyte INCY Common Stock | Directly | 24,424 | $115.87 | $2.8M | 5.9% | Form 4, Jun 8, 2026 |
| Immunome IMNM Common Stock | Directly | 43,415 | $16.61 | $721K | 1.5% | Form 4, Jun 5, 2026 |
| Keros Therapeutics KROS Common Stock | Directly | 19,592 | $11.39 | $223K | 0.5% | Form 4, Aug 17, 2026 |
| BioMarin Pharmaceutical BMRN Common Stock | Shares held as UTMA custodian for child 1 | 100 | $61.42 | $6K | 0.0% | Form 4, May 20, 2024 |
Share counts are the amounts Jean Jacques Bienaime reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Jean Jacques Bienaime's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/S ASND Ordinary Shares | Directly Not valued: reported in home-market shares, which trade in the US as depositary shares at a different ratio | 2,900 | $255.96 | $742K | — | Form 4, Aug 14, 2026 |
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Bought | KROS | 1,000 | $10.27 | $10K | View |
| Aug 14, 2026 | Bought | ASND | 1,100 | $245.85 | $270K | View |
| Aug 14, 2026 | Bought | ASND | 900 | $246.91 | $222K | View |
| Jul 15, 2026 | Bought | KROS | 1,000 | $10.61 | $11K | View |
| Jun 15, 2026 | Bought | KROS | 1,000 | $10.19 | $10K | View |
| Jun 5, 2026 | Sold | IMNM | 500 | $19.44 | $10K | View |
| Jun 5, 2026 | Sold | IMNM | 10,000 | $19.41 | $194K | View |
| Jun 5, 2026 | Bought | IMNM | 6,000 | $19.48 | $117K | View |
| Jun 5, 2026 | Bought | IMNM | 3,500 | $19.46 | $68K | View |
| Jun 5, 2026 | Bought | IMNM | 1,000 | $19.27 | $19K | View |
| May 29, 2026 | Bought | ASND | 200 | $223.76 | $45K | View |
| May 29, 2026 | Bought | ASND | 100 | $223.50 | $22K | View |
| May 29, 2026 | Bought | ASND | 200 | $222.30 | $44K | View |
| May 26, 2026 | Bought | ASND | 200 | $239.37 | $48K | View |
| May 26, 2026 | Bought | ASND | 200 | $236.24 | $47K | View |
| May 15, 2026 | Bought | KROS | 1,000 | $10.58 | $11K | View |
| May 15, 2026 | Bought | IMNM | 5,000 | $20.70 | $104K | View |
| Apr 15, 2026 | Bought | KROS | 1,000 | $11.70 | $12K | View |
| Mar 11, 2026 | Bought | IMNM | 1,000 | $21.55 | $22K | View |
| Mar 10, 2026 | Bought | IMNM | 1,000 | $22.12 | $22K | View |
| Mar 9, 2026 | Bought | KROS | 2,000 | $11.21 | $22K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 2617 | Andrew S. Marsh Chair and CEO, Entergy. New Orleans, LA | $48.1M |
| 2618 | Alexander M. Liberman Chief Legal Officer, Medline. Northfield, IL | $48.1M |
| 2619 | David P. Poole SVP & General Counsel, Range Resources. Morgantown, WV | $48.1M |
| 2620 | Jean Jacques Bienaime Director, BioMarin Pharmaceutical. Lexington, MA | $48.1M |
| 2621 | Chris Rogers President and CEO, Maplebear. San Francisco, CA | $48.1M |
| 2622 | Stacey Friedman General Counsel, JPMorgan Chase &. New York, NY | $48.1M |
| 2623 | Charlotte Guyman Director, Berkshire Hathaway. Medina, WA | $48.0M |
Other BioMarin Pharmaceutical insiders
All BMRN insiders- Alexander Hardy$13.2MChief Executive Officer. #7132 overall
- Henry J. Fuchs$11.4MPresident, Worldwide R&D. #7978 overall
- Richard A. Meier$7.8MDirector. #10567 overall
- Brian Mueller$7.6MEVP, Chief Financial Officer. #10767 overall
- Elaine J. Heron$6.0MDirector. #6863 overall
- Charles Greg Guyer$5.2MEVP, Chief Technical Officer. #14124 overall
Questions
How much stock does Jean Jacques Bienaime own?
Jean Jacques Bienaime holds $48,071,924 in listed stock based on SEC filings and current prices, mostly BioMarin Pharmaceutical (BMRN). That ranks 2620th on the Stock Rich List.
Is this Jean Jacques Bienaime's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Jean Jacques Bienaime last buy or sell stock?
The most recent open-market trade on file is a purchase of 1,000 KROS shares on Aug 17, 2026 at $10.27.